60th Legislature

1	HOUSE BILL NO. 449
2	INTRODUCED BY POMNICHOWSKI, EBINGER, FRANKLIN, HAMILTON, WILMER
3	
4	A BILL FOR AN ACT ENTITLED: "AN ACT TRANSFERRING BUPRENORPHINE FROM A SCHEDULE V DRUG
5	TO A SCHEDULE III DRUG; AMENDING SECTIONS 50-32-226 AND 50-32-232, MCA; AND PROVIDING AN
6	IMMEDIATE EFFECTIVE DATE."
7	
8	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
9	
10	Section 1. Section 50-32-226, MCA, is amended to read:
11	"50-32-226. Specific dangerous drugs included in Schedule III. Schedule III consists of the drugs
12	and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this
13	section.
14	(1) Stimulants. Unless specifically excepted or listed in another schedule, any material, compound,
15	mixture, or preparation that contains any quantity of the following substances is a stimulant having a stimulant
16	effect on the central nervous system, including salts, isomers (whether optical, position, or geometric), and salts
17	of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific
18	chemical designation:
19	(a) benzphetamine;
20	(b) chlorphentermine;
21	(c) clortermine; and
22	(d) phendimetrazine.
23	(2) Depressants. Unless specifically excepted or listed in another schedule, any material, compound,
24	mixture, or preparation that contains any quantity of the following substances is a depressant having a depressant
25	effect on the central nervous system:
26	(a) any compound, mixture, or preparation containing amobarbital, secobarbital, or pentobarbital or any
27	salt of any of these drugs and one or more other active medicinal ingredients that are not listed in any schedule;
28	(b) any suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of any
29	of these drugs approved by the federal food and drug administration for marketing only as a suppository;
30	(c) any substance that contains any quantity of a derivative of barbituric acid or any salt of barbituric acid;
	Legislative Services -1 - Division

1	(d) chlorhexadol;
2	(e) lysergic acid;
3	(f) lysergic acid amide;
4	(g) methyprylon;
5	(h) sulfondiethylmethane;
6	(i) sulfonethylmethane;
7	(j) sulfonmethane; and
8	(k) tiletamine and zolazepam or any of their salts. A trade or other name for a tiletamine-zolazepam
9	combination product is telazol. A trade or other name for tiletamine is 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
10	A trade or other name for zolazepam is 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
11	[1,4]-diazepin-7(1H)-one, flupyrazapon.
12	(3) Nalorphine.
13	(4) Narcotic drugs. Unless specifically excepted or listed in another schedule, any material, compound,
14	mixture, or preparation containing any of the following is a narcotic drug, including its salts calculated as the free
15	anhydrous base or alkaloid in the following limited quantities:
16	(a) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit,
17	with an equal or greater quantity of an isoquinoline alkaloid of opium;
18	(b) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit,
19	with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
20	(c) not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than
21	15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
22	(d) not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than
23	15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic
24	amounts;
25	(e) not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per
26	dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
27	(f) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per
28	dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
29	(g) not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25
30	milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
	Legislative Services - 2 - Division

HB0449.02

1	Of
2	(h) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active,
3	nonnarcotic ingredients in recognized therapeutic amounts <u>; or</u>
4	(i) any material, compound, mixture, or preparation containing buprenorphine.
5	(5) Anabolic steroids. The term "anabolic steroid" means any drug or hormonal substance, chemically
6	and pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids, that
7	promotes muscle growth. Unless specifically excepted or listed in another schedule, any material, compound,
8	mixture, or preparation containing any quantity of the following substances is an anabolic steroid, including salts,
9	isomers, and salts of isomers whenever the existence of those salts of isomers is possible within the specific
10	chemical designation:
11	(a) boldenone;
12	(b) chlorotestosterone, also known as 4-chlortestosterone;
13	(c) clostebol;
14	(d) dihydrochlormethyltestosterone;
15	(e) dihydrotestosterone, also known as 4-dihydrotestosterone;
16	(f) drostanolone;
17	(g) ethylestrenol;
18	(h) fluoxymesterone;
19	(i) formebulone, also known as formebolone;
20	(j) mesterolone;
21	(k) methandienone;
22	(I) methandranone;
23	(m) methandriol;
24	(n) methandrostenolone;
25	(o) methenolone;
26	(p) methyltestosterone;
27	(q) mibolerone;
28	(r) nandrolone;
29	(s) norethandrolone;
30	(t) oxandrolone;



1	(u) oxymestrone;
2	(v) oxymetholone;
3	(w) stanolone;
4	(x) stanozolol;
5	(y) testolactone;
6	(z) testosterone; or
7	(aa) trenbolone."
8	
9	Section 2. Section 50-32-232, MCA, is amended to read:
10	"50-32-232. Specific dangerous drugs included in Schedule V. Schedule V consists of the drugs and
11	other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this section.
12	(1) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material,
13	compound, mixture, or preparation containing buprenorphine and its salts is included in this category.
14	(2)(1) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or
15	preparation containing any of the following is a narcotic drug, including its salts, calculated as the free anhydrous
16	base or alkaloid in limited quantities as set forth in subsections (2)(a) (<u>1)(a)</u> through (2)(f) (<u>1)(f)</u> , which include one
17	or more nonnarcotic, active medicinal ingredients in sufficient proportion to confer upon the compound, mixture,
18	or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
19	(a) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
20	(b) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
21	(c) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
22	(d) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate
23	per dosage unit;
24	(e) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; and
25	(f) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per
26	dosage unit.
27	(3)(2) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any
28	material, compound, mixture, or preparation that contains any quantity of pyrovalerone is a stimulant having a
29	stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers."
30	

- 4 -

Legislative Services Division

1 <u>NEW SECTION.</u> Section 3. Effective date. [This act] is effective on passage and approval.

2

- END -

